Menstrual Migraine: The Evidence-Based Supplement Protocol

← Back to articles

Menstrual migraine — attacks clustered around the perimenstrual drop in estrogen, roughly two days before through three days into bleeding — affects a large share of women with migraine. These attacks tend to be longer, more severe, and more treatment-resistant than attacks at other times of the cycle. The mainstays are acute therapy (triptans, NSAIDs) and, when attacks are predictable, short-term perimenstrual prophylaxis: a 2010 review graded transdermal estradiol and the longer-acting triptans frovatriptan and naratriptan as having grade B evidence for this window. Supplements play a secondary, preventive role. The honest caveat up front: almost all of the supplement evidence comes from general migraine-prevention trials, not menstrual migraine specifically, so it is extrapolated. Only magnesium has a dedicated (and small, old) menstrual-migraine trial.

Magnesium — the one with menstrual-specific data

Magnesium is the most relevant supplement here because it is the only one tested in menstrual migraine itself. In a 1991 double-blind, placebo-controlled trial of 20 women with menstrual migraine, oral magnesium pyrrolidone carboxylic acid (360 mg/day from day 15 of the cycle until menses) reduced the number of headache days and premenstrual complaints versus placebo. More broadly, a 2016 meta-analysis of randomized trials found that oral magnesium supplementation reduced migraine frequency and intensity (pooled odds ratios around 0.20–0.27 for the prophylaxis trials). Magnesium is inexpensive and well tolerated; the main side effect is diarrhea (less with glycinate or citrate than oxide). Reasonable approach: daily magnesium, often with attention to the late-luteal/perimenstrual window. Grade: modest but among the better-supported options. See our magnesium and migraine piece.

Riboflavin (vitamin B2) — solid for general migraine, extrapolated here

The rationale is mitochondrial: migraine brains may have a relative energy deficit, and riboflavin is a cofactor in mitochondrial electron transport. In Schoenen's 1998 randomized trial (55 patients), 400 mg/day cut attack frequency, with 59% of riboflavin patients improving by at least half versus 15% on placebo (number-needed-to-treat about 2). It is cheap, very safe (harmless yellow urine is the main "effect"), and a sensible component of prophylaxis — though it has not been tested in menstrual migraine specifically. See our riboflavin piece.

CoQ10 — same mitochondrial rationale, smaller evidence

CoQ10 shares riboflavin's energy-metabolism logic. In a 2005 randomized trial (42 patients), CoQ10 300 mg/day (as 100 mg three times daily) beat placebo for attack frequency and headache days, with a 50%-responder rate of 48% versus 14%. The evidence base is smaller and the supplement more expensive than riboflavin, but it is a reasonable add-on. Again, the menstrual-subtype data are extrapolated from general migraine trials.

Vitamin B6 — weak, luteal-phase rationale only

Vitamin B6 appears in premenstrual-syndrome reviews with limited, low-quality evidence for luteal-phase symptoms; a systematic review of PMS interventions lists pyridoxine among options with weak supporting data. Its role in menstrual headache specifically is not established. If used, cap chronic intake at about 100 mg/day — higher long-term doses cause a sensory peripheral neuropathy. Treat B6 as optional and unproven rather than a core element.

Feverfew — low-certainty

Feverfew (Tanacetum parthenium) is a traditional migraine herb. The 2015 Cochrane review (six trials, 561 patients) graded the evidence low: the most rigorous recent trial found feverfew reduced attacks by only about 0.6 per month more than placebo, while older positive trials were small. It is generally well tolerated (mild GI upset, mouth ulcers); discontinue gradually because of a possible rebound-headache syndrome. A minor, optional adjunct at best, with no menstrual-specific data.

What to be cautious with

Be careful with butterbur: although some migraine trials were positive, unprocessed butterbur contains hepatotoxic pyrrolizidine alkaloids and has been pulled from several markets over liver-injury reports — only certified PA-free extracts should ever be considered, and many clinicians avoid it entirely. Do not combine 5-HTP with triptans, SSRIs/SNRIs, or other serotonergic drugs because of serotonin-syndrome risk. Skip generic "hormone balance" blends without an evidence base, and discuss chasteberry (vitex) with a clinician if you are trying to conceive or on hormonal therapy.

How to run the protocol

First, confirm the pattern: keep a headache diary against your cycle, since true menstrual or menstrually-related migraine changes the strategy. The supplement core is magnesium plus riboflavin 400 mg/day, with CoQ10 (300 mg/day) as an optional add-on; feverfew and B6 are minor extras with weaker support. For predictable perimenstrual attacks, ask a clinician about short-term prophylaxis (a longer-acting triptan or transdermal estradiol around the cycle) — these have better evidence than any supplement. Give a preventive regimen 8–12 weeks before judging it; a meaningful response is roughly a 50% reduction in monthly migraine days. If attacks remain disabling, a neurology referral for triptan or CGRP-targeted therapy is appropriate.